
AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
How to buy Abcellera Biologics Inc stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ABCL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Abcellera Biologics Inc stock price (NASDAQ: ABCL)
Use our graph to track the performance of ABCL stocks over time.Abcellera Biologics Inc shares at a glance
Latest market close | $7.54 |
---|---|
52-week range | $5.42 - $14.97 |
50-day moving average | $9.01 |
200-day moving average | $10.53 |
Wall St. target price | $28.33 |
PE ratio | 14.85 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.50 |
Buy Abcellera Biologics Inc stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Abcellera Biologics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Abcellera Biologics Inc price performance over time
Historical closes compared with the close of $7.54 from 2023-03-31
1 week (2023-03-22) | 3.15% |
---|---|
1 month (2023-02-28) | -10.24% |
3 months (2022-12-29) | -24.98% |
6 months (2022-09-29) | -23.45% |
1 year (2022-04-01) | -25.57% |
---|---|
2 years (2021-04-01) | -75.45% |
3 years (2020-03-28) | N/A |
5 years (2018-03-28) | N/A |
Is Abcellera Biologics Inc stock undervalued or overvalued?
Valuing Abcellera Biologics Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcellera Biologics Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
To put Abcellera Biologics Inc's EBITDA into context you can compare it against that of similar companies.
- Genmab AS (GMAB.US): USD$6.7 billion
- XBiotech (XBIT.US): USD$-31876000
- Aridis Pharmaceuticals (ARDS.US): USD$-30581000
Abcellera Biologics Inc financials
Revenue TTM | $485.4 million |
---|---|
Operating margin TTM | 44.6% |
Gross profit TTM | $311.1 million |
Return on assets TTM | 9.47% |
Return on equity TTM | 14.03% |
Profit margin | 32.66% |
Book value | $4.30 |
Market capitalisation | $2.2 billion |
TTM: trailing 12 months
Abcellera Biologics Inc share dividends
We're not expecting Abcellera Biologics Inc to pay a dividend over the next 12 months.
Abcellera Biologics Inc share price volatility
Over the last 12 months, Abcellera Biologics Inc's shares have ranged in value from as little as $5.42 up to $14.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcellera Biologics Inc's is -0.0916. This would suggest that Abcellera Biologics Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Abcellera Biologics Inc has bucked the trend.
To put Abcellera Biologics Inc's beta into context you can compare it against those of similar companies.
- Genmab AS (GMAB.US): 0.7133
- XBiotech (XBIT.US): 1.1873
- Aridis Pharmaceuticals (ARDS.US): 1.0658
Abcellera Biologics Inc overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. .
Abcellera Biologics Inc in the news
7 Stocks to Bet On if You Want to Be Richer Than Elon Musk
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
Frequently asked questions
What percentage of Abcellera Biologics Inc is owned by insiders or institutions?Currently 28.641% of Abcellera Biologics Inc shares are held by insiders and 46.461% by institutions. How many people work for Abcellera Biologics Inc?
Latest data suggests 495 work at Abcellera Biologics Inc. When does the fiscal year end for Abcellera Biologics Inc?
Abcellera Biologics Inc's fiscal year ends in December. Where is Abcellera Biologics Inc based?
Abcellera Biologics Inc's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 What is Abcellera Biologics Inc's ISIN number?
Abcellera Biologics Inc's international securities identification number is: CA00288U1066
More guides on Finder
-
Best apps and platforms for ETF investing
The best trading apps come with low fees and are easy to use.
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
How to Buy Gold Stocks
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
Ask an Expert